• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novo Nordisk launches two new diabetes drugs in U.S.

February 5, 2018 By Sarah Faulkner

Novo NordiskNovo Nordisk (NYSE:NVO) today launched two new diabetes medications in pharmacies across the U.S.

The Danish company’s Ozempic product is a once-weekly GLP-1 receptor agonist designed to boost glycemic control in adults with Type II diabetes. The injection, administered in a pre-filled pen, won FDA approval in December.

Fiasp, a fast-acting mealtime insulin, is indicated for adults with Type I and Type II diabetes. The FDA gave the insulin aspart injection the go-ahead in September last year.

“With 1.5 million new patients diagnosed with diabetes each year, we must continue to innovate and bring to market new options to meet the diverse needs of patients,” David Moore, SVP of Novo Nordisk’s commercial business unit, said in prepared remarks.

“There is no one-size-fits-all approach to effectively managing diabetes and we are proud to add Ozempic and Fiasp to our market-leading portfolio to give patients new treatment options. Our robust portfolio of diabetes products addresses the concerns and needs of people with diabetes, particularly around dosing and administration.”

Earlier this month, Novo Nordisk shares fell after the insulin-maker missed expectations on Wall Street with its fourth quarter and full-year financial results.

The company posted profits of $1.38 billion on sales of $4.68 billion for the 3 months ended Dec. 31, for bottom-line loss of -5% on sales loss of -5% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 57¢, behind consensus on The Street, where analysts were looking for sales of $4.86 billion.

The company also noted that its board’s chairman, Goran Ando, has decided not to seek re-election this year and that Helge Lund, a current member of the board, is slated to take the helm.

There are other personnel changes on the horizon for Novo Nordisk. The company’s SVP of corporate finance, Karsten Munk Knudsen, plans to assume the role of CFO in February this year, at which time the company’s existing chief finance exec, Jesper Brandgaard, will stay on as EVP of biopharm and legal affairs.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS